EP Patent

EP2001892A2 — Imidazolothiazole compounds for the treatment of disease

Assigned to Ambit Bioscience Corp · Expires 2008-12-17 · 17y expired

What this patent protects

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

USPTO Abstract

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

Drugs covered by this patent

Patent Metadata

Patent number
EP2001892A2
Jurisdiction
EP
Classification
—
Expires
2008-12-17
Drug substance claim
No
Drug product claim
No
Assignee
Ambit Bioscience Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.